Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Stock Information for Galectin Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galectin Therapeutics Inc.

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
Cassava Reports Q1 2025 Financials Results, Provides Business Update
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Cassava Sciences Licenses Simufilam Method of Treatment Patent
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.